CMPS

#2337
COMPASS Pathways Plc American Depository Shares
6.9000
-3.77%
版块:
基础:
利润货币:
日范围
6.9000
6.9000
年范围
4.9000
8.9000
日变化
-3.77%
每月变动
-1.85%
6个月变化
+8.32%
年变化
+8.32%
前一天收盘价
7.1700
Open
6.9000
Bid
Ask
Low
6.9000
High
6.9000
交易量
62
Open full chart

Financials

Overview 声明 Statistics Dividends
Quarterly Annual
Income statement Balance sheet Cash flow
Value Q3, 24Q4, 24Q1, 25Q2, 25Q3, 25 TTM

COMPASS Pathways Plc - American Depository Shares

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine. Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use.

新闻